Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$0.98 USD
0.00 (-0.22%)
Updated May 13, 2024 04:00 PM ET
After-Market: $0.99 +0.01 (0.79%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Rigel Pharmaceuticals, Inc. [RIGL]
Reports for Purchase
Showing records 61 - 80 ( 112 total )
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tavalisse Profile Continues to Improve, Led by Durability
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q18 Results; Early Positive Traction for Tavalisse Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Asian Partnership Delivered Well Ahead of Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Investor Day Takeaways; Tavalisse Positioned for Success; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q18 Results; Early Tavalisse Launch Data a Pleasant Surprise
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pipeline Expands as Expected; Feedback at ASCO was Positive for Tavalisse
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q18 Results; Pressing Play on May 29 at ASCO for Tavalisse Launch; Target Adjusted to $7.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Whoomp There It Is! Tavalisse Approved; Target Increased to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
IgAN Bump Ahead of ITP PDUFA; Don''t Lose Track of Big Picture; Target Adjusted to $6.70
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2017 Results; Hot and Heavy PDUFA Watch; Continue to Project Positive Outcome for Tavalisse
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Putting Spotlight on AIHA as Lead Follow-On Indication; ITP FDA Answer Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Race Toward April PDUFA; Market Should Be Happy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Impressive Stability Data at ASH; The FDA Should Like It Too; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q17 Results; Looking to Be the Belle at the Platelet Ball; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Fostamatinib Time to Shine Is Coming as Soon as April 2018 and Not Too Far Off; Assuming Coverage at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q17: With Tavalisse Filing Underway We Await Regulatory Developments
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reflecting BerGenBio Market Valuation in Our DCF Raises PT to $6 From $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q16: Fosta Filing and BerGenBio Deals to Start an Interesting Year; PT Down to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S